Loading: 100%
Bohai Pharmaceuticals Group, Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees (as per )no data available
Sector , , no data available
Ticker BOPHno data available
Financial year endsFY ends End of Juneno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 170,00,20,40,60,8
datesClosing price (adj.)
13.10.20170.01
11.10.20170.25
04.10.20170.25
27.09.20170.25
20.09.20170.25
13.09.20170.25
06.09.20170.25
30.08.20170.30
23.08.20170.30
16.08.20170.30
09.08.20170.30
02.08.20170.30
26.07.20170.30
19.07.20170.45
12.07.20170.45
05.07.20170.44
27.06.20170.44
20.06.20170.44
13.06.20170.20
06.06.20170.30
30.05.20170.35
23.05.20170.30
16.05.20170.30
09.05.20170.30
02.05.20170.30
25.04.20170.45
18.04.20170.40
11.04.20170.38
04.04.20170.63
28.03.20170.59
21.03.20170.55
14.03.20170.48
07.03.20170.49
28.02.20170.45
21.02.20170.50
14.02.20170.50
07.02.20170.54
31.01.20170.48
24.01.20170.50
17.01.20170.54
10.01.20170.52
03.01.20170.58
27.12.20160.54
19.12.20160.47
12.12.20160.35
05.12.20160.50
28.11.20160.42
21.11.20160.49
14.11.20160.50
07.11.20160.50
31.10.20160.50
24.10.20160.35
17.10.20160.33
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
0.01n/a
Market Capitalisation
in million USD
0n/a
Enterprise Value
in million USD
0n/a
Common Shares Outstanding
as per Sep 30, 2014
19,249,285n/a
Preferred Shares Outstanding
as per Sep 30, 2014
n/a
Average Basic Shares Outstanding
TTM
18,165,079n/a
Average Diluted Shares Outstanding
TTM
21,572,898n/a
Index Membership
n/a
Business Summary
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 0n/a
Receivables 0n/a
Total Current Assets 0n/a
PP&E 0n/a
Total Assets 0n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 0n/a
Long-Term Debt 0n/a
Total Liabilities 0n/a
Total Equity 0n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value n/a
Other Ratios
Current Ratio 0.0%n/a
Liabilities to Equity Ratio 0.0%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (18 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14
Net revenues
81
137
152
175
Cost of revenues
17
34
37
42
Gross Profit
64
104
115
133
Selling, general and administrative
46
73
83
98
Depreciation and amortization
0
3
3
3
Impairment charge- drug formula
0
0
2
0
Total operating expenses
46
75
88
100
Income from operations
18
28
27
32
Interest income
0
0
0
0
Interest expense
-4
-11
-2
-2
Other (expenses)
0
0
0
1
Change in fair value of derivative liabilities
5
0
1
0
Total other (expenses) income
1
-11
-1
-1
Income before provision for income taxes
19
17
26
32
Provision for income taxes
5
7
-7
-10
Net income
14
10
19
22
Remarks
restated on Oct 16, 2012 n/a
calculated values,
restated on Sep 27, 2013 n/a
calculated values,
restated on Oct 21, 2014 n/a
calculated values,
restated on Oct 21, 2014 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (40 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14
Assets
Cash
13
18
7
23
Restricted cash
0
9
13
13
Accounts receivable
16
30
39
42
Inventories
2
4
3
5
Prepaid expenses and other current assets
1
1
0
1
Total current assets
32
62
62
83
Property, plant and equipment, net
5
12
18
21
Prepayment for property, plant and equipment
0
1
1
0
Intangible assets - pharmaceutical formulas
25
26
14
14
Long term prepayments - land use right, net
18
19
38
38
Other intangible assets, net
0
21
28
24
Goodwill
0
5
5
5
Debt issue costs, net
0
0
0
0
Total non-current assets
48
83
104
102
Total assets
80
145
166
185
Liabilities and owners' equity
Notes payable
0 0
0 0
10 9707638
10 9745795
Convertible notes, net
1 1132103
10 10036000
8 8464500
0 0
Short-term borrowings
1 920554
0 0
0 0
5 4872899
Accounts payable
1 1291907
3 3334101
5 5081913
6 6107200
Accrued expenses
4 4312333
8 8478054
12 12185615
16 15718565
Land use right payable
0 0
0 0
6 6471759
0 0
Income taxes payable
1 721771
2 2338825
2 2222476
3 3085929
Acquisition purchase price payable - current portion
0 0
5 5000000
0 0
0 0
Derivative liabilities - investor and agent warrants
1 937867
1 1211236
0 0
0 0
Due to related party
0 11980
0 36002
0 52830
0 55626
Total current liabilities
9 9328515
30 30434218
44 44186731
40 39586014
Acquisition purchase price payable - non-current portion
0 0
20 20300000
5 5000000
0 0
Covertible notes, net
0 0
0 0
0 0
7 7435800
Deferred tax liability
3 2878397
8 8161269
8 8048113
8 8143826
Total non-current liabilities
3 2878397
28 28461269
13 13048113
16 15579626
Total liabilities
12 12206912
59 58895487
57 57234844
55 55165640
COMMITMENTS, CONTINGENCIES, AND OTHER MATTERS
0 0
0 0
0 0
0 0
Common stock
0 17861
0 17861
0 17861
0 17965
Additional paid-in capital
18 18345574
25 24615353
25 24615353
25 24822499
Accumulated other comprehensive income
4 3559355
6 6236076
9 8999581
8 8114171
Statutory reserves
2 2201817
0 0
0 0
0 0
Retained earnings
44 43783400
56 55633242
75 74756759
97 96645974
Total stockholders' equity
68 67908007
87 86502532
108 108389554
130 129600609
Total liabilities and stockholders' equity
80 80114919
145 145398019
166 165624398
185 184766249
Remarks restated on Oct 16, 2012 n/a restated on Sep 27, 2013 n/a restated on Oct 21, 2014 n/a restated on Nov 14, 2014 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (50 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14
Net income
14
10
19
22
Bad debt expense
0
0
0
0
Depreciation and amortization
1
4
5
6
Impairment loss on intangible assets - pharmaceutical formulas
1
0
2
0
(Loss) on disposal of property, plant and equipment
0
0
0
0
Amortization of debt issue costs
1
0
0
0
Non-cash interest-convertible notes
2
9
0
0
Stock based compensation
0
0
0
0
Change in fair value of warrants
-5
0
-1
0
Convertible notes conversion
0
0
0
0
Deferred income taxes
0
0
0
0
Accounts receivable
-5
-6
-8
-3
Prepaid expenses and other current assets
0
0
0
0
Inventories
-1
-1
1
-2
Accounts payable
0
0
2
1
Accrued liabilities
1
3
1
0
Income taxes payable
0
1
0
1
Net cash provided by operating activities
11
21
21
25
Purchases of property, plant and equipment
0
-1
-4
0
Proceeds from disposal of property, plant and equipment
0
0
0
0
Purchase of drug formulas
-7
0
0
0
Land use rights payments
-7
0
-13
-6
Cash received in acquisition of business
0
1
0
0
Prepayment for property, plant and equipment
0
-1
0
1
Cash paid for acquisition of business
0
-10
-20
-5
Net cash used in investing activities
-14
-19
-38
-11
Proceeds from notes payable
-5
-3
0
0
Proceeds from short term borrowings
1
0
0
5
Proceeds from notes payable
0
0
10
10
Repayment of convertible notes
0
0
0
-10
Capital contribution from shareholder
0
6
0
0
Proceeds from issuance of common stock
2
0
0
0
Borrowing from related party
0
0
0
0
Repayment to related party
0
0
0
0
Repayment of convertible notes
0
0
-2
-1
Deposit of restricted cash-note payable
0
0
-5
5
Release of restricted cash-note payable
1
1
0
-5
Deposit of restricted cash-convertible note escrow deposit
0
-10
-3
0
Release of restricted cash-convertible note escrow deposit
0
0
5
0
Net cash provided by (used in) financing activities
-1
3
5
4
Effect of foreign currency translation on cash and cash equivalents
1
0
0
-2
Net increase (decrease) in cash and cash equivalents
-4
5
-11
16
Remarks
restated on Oct 16, 2012 n/a
calculated values,
restated on Sep 27, 2013 n/a
calculated values,
restated on Oct 21, 2014 n/a
calculated values,
restated on Oct 21, 2014 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo